170918-27-1

Basic information

• Product Name: 1,2-Benzenediamine, 3-methyl-4-nitro-
• Synonyms: 2,3-diamino-6-nitrotoluene
• CAS NO: 170918-27-1
• Molecular Formula: C7H9N3O2
• Molecular Weight: 167.16500
• Mol File: 170918-27-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 403.4±40.0 °C(Predicted)
• Density: 1.369±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 1,2-Benzenediamine, 3-methyl-4-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-Benzenediamine, 3-methyl-4-nitro-(170918-27-1)
• EPA Substance Registry System: 1,2-Benzenediamine, 3-methyl-4-nitro-(170918-27-1)

Safety Data

• Hazardous Substances Data: 170918-27-1(Hazardous Substances Data)

Usage

Physical state

Yellow crystalline solid

Primary uses

Synthesis of dyes and pigments, production of pharmaceuticals and agricultural chemicals

Hazard classification

Toxic and hazardous substance

Environmental impact

Potential negative impact on the environment

Health hazards

Skin and eye irritation upon contact

Carcinogenicity

Suspected human carcinogen (IARC and EPA)

Precautions

Proper handling and safety measures required when working with this chemical

Upstream product

• 10202-92-3 3-methyl-2,4-dinitroaniline 

Downstream Products

• 170918-13-5 1-tert-butoxycarbonyl-4-methyl-5-nitrobenzimidazole 
• 170918-28-2 4-methyl-5-nitrobenzimidazole 
• 171102-36-6 6-Amino-5-methylquinoxaline 
• 183278-00-4 5-methyl-6-nitroquinoxaline 

Relevant articles and documents

5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as α-adrenoceptor agonists with improved metabolic stability

Benzimidazole compounds having the generic structure: are used to treat alpha-2 mediated disorders, including nasal congestion, glaucoma, asthma, migraine, and diarrhea.

Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists

This invention involves compounds having the following structure: as described in the Claims; and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, as well as pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors.

6-(2-IMIDAZOLINYLAMINO) QUINOXALINE COMPOUNDS USEFUL AS alpha-2 ADRENORECEPTOR AGONISTS

The subject invention involves methods of treating nasal congestion comprising administration, to a human or lower animal in need of such treatment of a safe and effective amount of a compound having the following structure: STR1 wherein (a) R is unsubsti